抗前列腺干细胞抗原Cys-双抗体对胰腺癌的双模态免疫PET与近红外荧光成像
研究开发了靶向前列腺干细胞抗原(PSCA)的双标记探针A2cDb-800,可同时用于免疫PET和近红外荧光成像。在前列腺癌异种移植模型和患者来源胰腺导管腺癌异种移植模型中,该双模态探针实现了高对比度免疫PET显像和荧光信号,提示可能有助于PSCA阳性胰腺癌的定位和术中肿瘤边缘识别。
要点
- 双标记探针124I-A2cDb-800的放射化学纯度超过99%,免疫反应性为65%±4.5%(n=3)。
- 在PSCA阳性肿瘤中观察到特异性摄取,免疫PET图像对比度高,非特异性本底活性低。
- 双模态成像在患者来源胰腺导管腺癌异种移植模型中获得了高对比度的免疫PET/近红外荧光图像。
核心结论
- 使用抗PSCA cys-双抗体的双模态成像在患者来源胰腺导管腺癌异种移植模型中获得了高对比度的免疫PET/近红外荧光图像,提示该显像剂可能同时提供非侵入性全身显像以定位PSCA阳性胰腺癌和术中荧光图像引导的肿瘤边缘识别。
研究设计与样本
- 研究开发了基于A2 cys-双抗体(A2cDb)的双标记探针,靶向细胞表面前列腺干细胞抗原(PSCA),通过马来酰亚胺-IRDye800CW定点偶联至C端cys标签(A2cDb-800),并用124I直接放射性碘化得到124I-A2cDb-800。
- 在前列腺癌异种移植模型中评估了双模态示踪剂对PSCA表达肿瘤细胞的体内特异性和生物分布,并与单标记的124I-A2cDb进行比较。
- 患者来源胰腺导管腺癌异种移植模型(PDX-PDACs)在NSG小鼠皮下生长,并通过免疫PET筛选PSCA表达;使用双模态124I-A2cDb-800对PDX-PDAC荷瘤小鼠进行小动物PET/CT扫描,随后在去除皮肤后进行离体近红外荧光成像。
主要发现
- 双标记探针A2cDb-800的半数最大结合为4.3 nM,未损害integrity或亲和力。
- 124I-A2cDb-800的比活度为159±48 MBq/mg,放射化学纯度超过99%,免疫反应性为65%±4.5%(n=3)。
- 在PSCA阳性肿瘤中观察到特异性摄取,非特异性本底活性低,导致高对比度的免疫PET图像。
- 在注射双示踪剂124I-A2cDb-800的小鼠中,PSCA阳性肿瘤观察到荧光信号,周围组织背景摄取或自发荧光低。
- 离体生物分布证实124I-A2cDb-800和124I-A2cDb的肿瘤摄取相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic cancer has a high mortality rate due to late diagnosis and the tendency to invade surrounding tissues and metastasize at an early stage. A molecular imaging agent that enables both presurgery antigen-specific PET (immuno-PET) and intraoperative near-infrared fluorescence (NIRF) guidance might benefit diagnosis of pancreatic cancer, staging, and surgical resection, which remains the only curative treatment. Methods: We developed a dual-labeled probe based on A2 cys-diabody (A2cDb) targeting the cell-surface prostate stem cell antigen (PSCA), which is expressed in most pancreatic cancers. Maleimide-IRDye800CW was site-specifically conjugated to the C-terminal cys-tag (A2cDb-800) without impairing integrity or affinity (half-maximal binding, 4.3 nM). Direct radioiodination with 124I (124I-A2cDb-800) yielded a specific activity of 159 ± 48 MBq/mg with a radiochemical purity exceeding 99% and 65% ± 4.5% immunoreactivity (n = 3). In vivo specificity for PSCA-expressing tumor cells and biodistribution of the dual-modality tracer were evaluated in a prostate cancer xenograft model and compared with single-labeled 124I-A2cDb. Patient-derived pancreatic ductal adenocarcinoma xenografts (PDX-PDACs) were grown subcutaneously in NSG mice and screened for PSCA expression by immuno-PET. Small-animal PET/CT scans of PDX-PDAC-bearing mice were obtained using the dual-modality 124I-A2cDb-800 followed by postmortem NIRF imaging with the skin removed. Tumors and organs were analyzed ex vivo to compare the relative fluorescent signals without obstruction by other organs. Results: Specific uptake in PSCA-positive tumors and low nonspecific background activity resulted in high-contrast immuno-PET images. Concurrent with the PET studies, fluorescent signal was observed in the PSCA-positive tumors of mice injected with the dual-tracer 124I-A2cDb-800, with low background uptake or autofluorescence in the surrounding tissue. Ex vivo biodistribution confirmed comparable tumor uptake of both 124I-A2cDb-800 and 124I-A2cDb. Conclusion: Dual-modality imaging using the anti-PSCA cys-diabody resulted in high-contrast immuno-PET/NIRF images of PDX-PDACs, suggesting that this imaging agent might offer both noninvasive whole-body imaging to localize PSCA-positive pancreatic cancer and fluorescence image-guided identification of tumor margins during surgery.
引用
- Zettlitz KA, Tsai WK, Knowles SM, et al. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. J Nucl Med. 2018. PMID: 29602820. doi:10.2967/jnumed.117.207332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。